Clinical Trial Update: The Study of Different Dose Rituximab in the Treatment of ITP [Phase 4]

View source ↗

Summary

This clinical trial update reports a phase 4 study evaluating different doses of rituximab to treat immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Shandong University | Conditions: Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia | Phase 4 | Status: COMPLETED